Efficacy of lopinavir–ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis
Future virology
; 2022.
Article
in English
| EuropePMC | ID: covidwho-1678760
ABSTRACT
Aim:
To evaluate the efficacy and safety of lopinavir–ritonavir (LPV/r) therapy in treating hospitalized COVID-19 patients. Materials &methods:
Data from randomized and observational studies were included in meta-analyses. Primary outcomes were length of stay, time for SARS-CoV-2 test conversion, mortality, incidence of mechanical ventilation, time to body temperature normalization and incidence of adverse events.Results:
Twenty-four studies (n = 10,718) were included. LPV/r demonstrated no significant benefit over the control groups in all efficacy outcomes. The use of LPV/r was associated with a significant increase in the odds of adverse events.Conclusion:
Given the lack of efficacy and increased incidence of adverse events, the clinical use of LPV/r in hospitalized COVID-19 patients is not recommended.
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Type of study:
Reviews
Language:
English
Journal:
Future virology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS